Anavex Life Sciences Corp. (AVXL)
| Market Cap | 792.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.54M |
| Shares Out | 64.30M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $11.31 |
| Previous Close | $11.57 |
| Change ($) | -0.26 |
| Change (%) | -2.25% |
| Day's Open | 11.53 |
| Day's Range | 11.21 - 11.76 |
| Day's Volume | 466,847 |
| 52-Week Range | 3.42 - 28.70 |
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Shopify & GoDaddy
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...
Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET
Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time Conference Call and Webcast To be Held Thursday, February 11, 2021 4:30 pm Eastern Time
Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
Anavex Life Sciences (AVXL) stock is soaring higher Thursday on heavy trading despite a lack of news concerning the company. The post AVXL Stock: 6 Things for Investors to Know About Anavex Life Science...
Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have lit...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript
Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET
Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...
The company reported positive results from a phase 2 clinical trial.
Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal yea...
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge ...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for t...
Statistically s ignificant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)
Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
The biotech's drug appears to help patients with Parkinson's disease dementia.
C linically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics fo...
Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Globa...
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences Corp. (AVXL) CEO Dr.
Conference Call and Webcast Today at 11:00 a.m. ET Conference Call and Webcast Today at 11:00 a.m. ET
Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical Study Compas...
Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time
Anavex Life Sciences is developing drugs for the treatment of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Rett Syndrome, fragile X, Angelman syndrome, and infantile spasms.
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is (AVXL) Outperforming Other Medical Stocks This Year?
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
Is (AVXL) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip... [Read more...]
| Industry Biotechnology | |
| CEO Christopher Missling | Employees 20 |
| Stock Exchange NASDAQ | Ticker Symbol AVXL |
Analyst Forecasts
According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is 18.80, which is an increase of 66.22% from the latest price.